BioDelivery Sciences International Inc. (NASDAQ:BDSI)’s share price shot up 5.1% during trading on Wednesday . The company traded as high as $2.81 and last traded at $2.47, with a volume of 1,480,457 shares. The stock had previously closed at $2.35.

A number of equities research analysts recently weighed in on the stock. FBR & Co lifted their price objective on shares of BioDelivery Sciences International from $9.00 to $12.00 and gave the company an “outperform” rating in a report on Wednesday, May 4th. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “hold” rating to a “strong sell” rating in a report on Friday, May 6th. Piper Jaffray Cos. restated an “outperform” rating on shares of BioDelivery Sciences International in a report on Friday, March 11th. Cantor Fitzgerald lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and reduced their price target for the company from $9.00 to $5.00 in a report on Wednesday, May 11th. Finally, Roth Capital restated a “buy” rating on shares of BioDelivery Sciences International in a report on Monday, March 28th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $8.38.

The company has a 50-day moving average of $2.32 and a 200-day moving average of $3.30. The stock’s market capitalization is $130.77 million.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.01. The company had revenue of $3 million for the quarter, compared to analysts’ expectations of $2.96 million. The company’s revenue for the quarter was down 77.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.16) earnings per share. Equities research analysts forecast that BioDelivery Sciences International Inc. will post ($1.19) earnings per share for the current year.

A number of hedge funds and institutional investors recently made changes to their positions in the company. Royce & Associates LLC raised its position in shares of BioDelivery Sciences International by 6.2% in the fourth quarter. Royce & Associates LLC now owns 1,487,800 shares of the specialty pharmaceutical company’s stock valued at $7,127,000 after buying an additional 87,200 shares during the period. Penn Capital Management Co. Inc. raised its position in shares of BioDelivery Sciences International by 6.8% in the fourth quarter. Penn Capital Management Co. Inc. now owns 1,314,623 shares of the specialty pharmaceutical company’s stock valued at $6,297,000 after buying an additional 84,031 shares during the period. Russell Frank Co raised its position in shares of BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock valued at $5,151,000 after buying an additional 394,272 shares during the period. Turner Investments L.P. raised its position in shares of BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock valued at $4,315,000 after buying an additional 321,290 shares during the period. Finally, Bank of Montreal Can raised its position in shares of BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock valued at $3,971,000 after buying an additional 28,838 shares during the period.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.